Latest news, events and publications from EPICS Therapeutics

EPICS Publishes Discovery and Optimization of its METTL3 Inhibitor EP102 in Journal of Medicinal Chemistry

EPICS Therapeutics announces publication in the Journal of Medicinal Chemistry detailing the discovery and optimization of EP102, its clinical-stage METTL3 inhibitor designed to target cancer at the RNA level through a novel epigenetic mechanism.

EPICS to Present Preclinical Data on METTL3 Inhibitor EP102 at American Association for Cancer Research Annual Meeting 2026

April 17-22, 2026, San Diego Convention Center, San Diego, California.

Cresset Discovery Accelerates METTL3 Inhibitor Design and Optimization

In collaboration with EPICS Therapeutics, Cresset Discovery, a specialist in computational drug design, has developed an integrated modeling workflow to accelerate the discovery and optimization of a METTL3 inhibitor. By leveraging its expertise in molecular modeling and proprietary technology, Cresset enabled the rapid design and prioritization of novel compounds based on their three-dimensional shape and electrostatic properties.

EPICS To Present Preclinical Data on METTL3 Inhibitor EP102 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22 - 26, 2025.. Hynes Convention Center Boston, Massachusetts

EPICS’s In Silico Modeling Partner Publishes Study Featuring EP652 in Journal of Medicinal Chemistry

EPICS to Attend BIO-Europe 2025 in Vienna

November 3–5, 2025. Vienna Congress and Convention Center, Vienna, Austria.

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22 - 26, 2025. Hynes Convention Center Boston, Massachusetts.

EPICS at the BIO Investment Convention 2025 in Charleroi

October 16, 2025. Palais des expositions de Charleroi, Charleroi, Belgium.
​

​

EPICS Therapeutics Announces First Cohort Dosed with EP102 in First-In-Patient Oncology Trial and Securement of Additional Financing

Amelioration of Central Nervous System Autoimmunity Through FFAR2 Agonism Is Associated With Changes in Gut Microbiota

EPICS Therapeutics publishes the medicinal chemistry and efficacy of its proprietary METTL3 inhibitors in the Journal of Medicinal Chemistry

EPICS Therapeutics Appoints Graeme Fraser PhD, Chief Executive Officer and Raises €12M in Series A Preferred Financing to Advance its Oncology Pipeline